Organization
Chongqing University Cancer Hospital, Chonqqing, China
1 abstract
Abstract
Preliminary safety and efficacy of TQB2930, a HER2-targeted bispecific antibody in patients with advanced breast cancer: Results from a phase 1b study.Org: Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China, Harbin Medical University Cancer Hospital, Harbin, China, Chongqing University Cancer Hospital, Chonqqing, China, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center,